Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: Response to treatment with bevacizumab

American Journal of the Medical Sciences

Volumn 343, Issue 3, 2012, Pages 249-251

  Fleagle, Jessica M ^a   Bobba, Ravi K ^a   Kardinal, Carl G ^a   Freter, Carl E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Bevacizumab; Hereditary hemorrhagic telangiectasia; Iron deficiency anemia

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BEVACIZUMAB; ENDOGLIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; FERROUS SULFATE; HEMOGLOBIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VANCOMYCIN;

ADULT; ARTICLE; BACTEREMIA; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; CAUTERIZATION; DRUG RESPONSE; EPISTAXIS; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; MEDICAL HISTORY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIPLE CYCLE TREATMENT; MUTATION; NEOVASCULARIZATION (PATHOLOGY); RENDU OSLER WEBER DISEASE; STOMACH ANTRUM VASCULAR ECTASIA; TREATMENT RESPONSE;

EID: 84857645067     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3182429866     Document Type: Article

References (23)

1. Porteous ME, Burn J, Proctor SJ. Hereditary haemorrhagic telangiectasia: a clinical analysis. J Med Genet 1992;29:527-30.
2. Westermann CJ, Rosina AF, De Vries V, et al. The prevalence and manifestations of hereditary hemorrhagic telangiectasia in the Afro-Caribbean population of the Netherlands Antilles: a family screening. Am J Med Genet A 2003;116A:324-8.
3. Johnson DW, Berg JN, Gallione CJ, et al. A second locus for hereditary hemorrhagic telangiectasia maps to chromosome 12. Genome Res 1995;5:21-8.
4. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGFbeta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-51.
5. Romer W, Burk M, Schneider W. [Hereditary hemorrhagic telangiectasia (Osler's disease)]. Dtsch Med Wochenschr 1992;117:669-75.
6. Olitsky SE. Hereditary hemorrhagic telangiectasia: diagnosis and management. Am Fam Physician 2010;82:785-90.
7. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-34.
8. Begbie ME, Wallace GM, Shovlin CL. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 2003;79:18-24.
9. Kjeldsen AD, Oxhøj H, Andersen PE, et al. Pulmonary arteriovenous malformations: screening procedures and pulmonary angiography in patients with hereditary hemorrhagic telangiectasia. Chest 1999;116: 432-9.
10. Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66-7.
11. Boehm S, Rothermundt C, Hess D, et al. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly-a mini-review. Gerontology 2010;56:303-9.
12. Bashshur ZF, Haddad ZA, Schakal A, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a oneyear prospective study. Am J Ophthalmol 2008;145:249-56.
13. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007;41:614-25.
14. Simonds J, Miller F, Mandel J, et al. The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope 2009;119:988-92.
15. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85:631-2.
16. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006;43:97-110.
17. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 2005;90:818-28.
18. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
19. Cirulli A, Liso A, D'Ovidio F, et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003;110:29-32.
20. Ozawa CR, Banfi A, Glazer NL, et al. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J Clin Invest 2004;113:516-27.
21. Mitchell A, Adams LA, MacQuillan G, et al. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210-3.
22. Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009;360:2143-4.
23. Fleagle JM, Bobba RK, Khozouz RF, et al. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab. J Clin Oncol 2011;29(suppl):abstract e13521.